Date	e:	3/5/2024	
You	ır Name:	Wilson X. Wang	
Maı	nuscript Title:	Crizanlizumab for Retinal Vasculopat clinical study	thy with Cerebral Leukoencephalopathy in a Phase 2
mus	based Author (if yes, st fill out Open Payme tion below):		
Mai	nuscript Number (if k	nown):	
			eee of Medical Journal Editors (ICMJE) on "Conflict of er conflicts of interest that might bias their work."
con affe indi	tent of your manuscriected by the content of icate a bias. If you are	pt. "Related" means any relation with for-prof f the manuscript. Disclosure represents a com in doubt about whether to list a relationship/	rectivities/interests listed below that are related to the fit or not-for-profit third parties whose interests may be mitment to transparency and does not necessarily activity/interest, it is preferable that you do so.
epic	demiology of hyperter		 For example, if your manuscript pertains to the manufacturers of antihypertensive medication, even if
	tem #1 below, report a me for disclosure is the		cript without time limit. For all other items, the time
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were
		relationship or indicate none (add rows as ne	
		relationship or indicate none (add rows as ne Time frame: Since the initial pl	eded) made to you or to your institution)
1	All support for the present manuscript (e.g.,		eded) made to you or to your institution) anning of the work
1	All support for the present manuscript (e.g., funding, provision	Time frame: Since the initial pl	eded) made to you or to your institution) anning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Time frame: Since the initial place. None Washington University MD5 Program: DeNard	eded) made to you or to your institution) anning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Time frame: Since the initial place. None Washington University MD5 Program: DeNard	anning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Time frame: Since the initial place. None Washington University MD5 Program: DeNard	anning of the work do Click the tab key to add additional rows.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
κ	Royalties or licenses	None None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

FOR US-BASED AUTHORS ONLY>>> OPEN PAYMENTS

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their Open Payments record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., https://openpaymentsdata.cms.gov/physician/1316209). To learn more about this new requirement, please refer to Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.

Open Payments URL:	Click or tap here to enter text.
Match Disclosure Form?	YES/NO
If no, please briefly explain discrepancy:	Click or tap here to enter text.

ICMJE DISCLOSURE FORM

Date:	3/2/2024
Your Name:	Dan Spiegelman
Manuscript Title:	Crizanlizumab for Retinal Vasculopathy with Cerebral Leukoencephalopathy in a Phase 2 clinical study
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	of the work Click the tab key to add additional rows.
	this item.	Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreement to answered every question and have not altered the wo	

Date	::	-	3/3/2024		
You	Name:	-	Prabakar Kumar Rao		
Man	uscript Title:		Crizanlizumab for Retinal Vasculopathy wit clinical study	h Cerebral Leukoencephalopathy in a Phase 2	
mus	pased Author (if yes, t fill out Open Paymo ion below):	-	YES		
Man	uscript Number (if k	(nown):			
-			position of the International Committee of I uthors is defined as "financial and other con	Medical Journal Editors (ICMJE) on "Conflict of flicts of interest that might bias their work."	
cont affe	ent of your manuscr cted by the content o	ipt. "Rela of the mar	ted" means any relation with for-profit or n	es/interests listed below that are related to the ot-for-profit third parties whose interests may be nt to transparency and does not necessarily /interest, it is preferable that you do so.	
epid		nsion, you	•	example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
In ite	om #1 holow ronart		. 6		
	ne for disclosure is th			vithout time limit. For all other items, the time	
	-	Name all		Specifications/Comments (e.g., if payments were made to you or to your institution)	e
	-	Name all	entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your institution)	e
fram	e for disclosure is th	Name all relations	entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	e
fram	e for disclosure is th	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution)	e
fram	All support for the present manuscript (e.g., funding, provision	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution	e
fram	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work	e
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution	e
fram 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution	e
fram 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all relations	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution Click the tab key to add additional rows.	e
fram 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Name all relations Researce	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one the to Prevent Blindness	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution Click the tab key to add additional rows.	e
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Name all relations Researce	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one the to Prevent Blindness Time frame: past 36 month	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution Click the tab key to add additional rows.	e
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all relations Researce	entities with whom you have this hip or indicate none (add rows as needed) Time frame: Since the initial planning one the to Prevent Blindness Time frame: past 36 month	Specifications/Comments (e.g., if payments were made to you or to your institution) of the work Institution Click the tab key to add additional rows.	e

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
ε	Royalties or licenses	None None	
4	Consulting fees	None None	
9	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	VRS Foundation Annual Update	Honoraria payment made directly to me
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	VRS Annual Update	Payment for hotel stay made directly to hotel on my behalf
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

	society, committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-financial interests	CEO Hark Vision – make low cost slit lamp cameras Payment directly to me
Plea	•	answered every question and have not altered the wording of any of the questions on this form.
FOR	US-BASED AU	THORS ONLY>>> OPEN PAYMENTS
recore must https:	d (past 2 years only) provide a brief expla ://openpaymentsdat	, those with a US National Provider Identifier [NPI]), it is now required they look up their Open Payments to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author mation on the ICMJE Form along with the Open Payment URL person record (e.g., ta.cms.gov/physician/1316209). To learn more about this new requirement, please refer to Van Gelder RN and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.
Ope	n Payments URL:	https://openpaymentsdata.cms.gov/physician/688771

Specifications/Comments (e.g., if payments were

made to you or to your institution)

Name all entities with whom you have this

relationship or indicate none (add rows as needed)

Match Disclosure Form?

discrepancy:

If no, please briefly explain

YES

Click or tap here to enter text.

anuscript Title:	Crizanlizumab for Retinal Vasculopathy with Cerebral Leukoencephalopathy in a Phase 2 clinical study
6-based Author (if yes, you ust fill out Open Payment ction below):	YES
anuscript Number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Clayco foundation	Payments made to the institution, Washington University
		Novartis	Supplied the drug being studied, crizanlizumab, free of charge
			Click the tab key to add additional rows.
Time frame: past 36 months		ns	
2	Grants or contracts from	⊠ None	
	any entity (if not indicated in item #1 above).	NIH NINDS RF1	Payments made to the institution, Washington University
		NIH NHLBI R01	Payments made to the institution, Washington University
		NIH NINDS U01	Payments made to the institution, Washington University

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Pfizer	2022, 2023 – Advisory Board; Payments made to Andria Ford.
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form.			

FOR US-BASED AUTHORS ONLY>>> OPEN PAYMENTS

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their Open Payments record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., https://openpaymentsdata.cms.gov/physician/1316209). To learn more about this new requirement, please refer to Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.

Open Payments URL:	https://openpaymentsdata.cms.gov/physician/599331
Match Disclosure Form?	YES
If no, please briefly explain discrepancy:	Click or tap here to enter text.

Date:		-	2/14/2024		
Your Name:		-	Rajendra Apte		
Manuscript Title:			Crizanlizumab for Retinal Vasculopathy with Cerebral Leukoencephalopathy in a Phase 2 Clinical Study		
US-based Author (if yes, you must fill out Open Payment section below):		-	YES		
Man	nuscript Number (if k	known):			
-			position of the International Committee of Nuthors is defined as "financial and other conf	Medical Journal Editors (ICMJE) on "Conflict of licts of interest that might bias their work."	
contraffed indice. The epid that	tent of your manuscr cted by the content of cate a bias. If you are author's relationship demiology of hyperte medication is not m	ript. "Rela of the mar e in doubt ps/activitie ension, you entioned	ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For each should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Clayco F Researc	Foundation The to Prevent Blindness To Fort Innovation Fund The Retina Research Fund Time frame: past 36 month	Washington University Washington University Washington University Washington University	
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
		Roche	Personal Compensation
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board,	None	

		The state of the s	cations/Comments (e.g., if payments were to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	■ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	■ None	
13	Other financial or non-financial interests	None	
Plea ⊠		t to the following statement to indicate your agreement: answered every question and have not altered the wording of	any of the questions on this form.

FOR US-BASED AUTHORS ONLY>>> OPEN PAYMENTS

For US-based authors (i.e., those with a US National Provider Identifier [NPI]), it is now required they look up their Open Payments record (past 2 years only) to confirm that it matches what is reported on the ICMJE Form. If there are discrepancies, the co-author must provide a brief explanation on the ICMJE Form along with the Open Payment URL person record (e.g., https://openpaymentsdata.cms.gov/physician/1316209). To learn more about this new requirement, please refer to Van Gelder RN and Siegfried CJ. ROI, COI, and the Ethical Obligations of Journals. Ophthalmology. 2022; 129: 602-604.

Open Payments URL:	https://openpaymentsdata.cms.gov/physician/159619
Match Disclosure Form?	NO
If no, please briefly explain discrepancy:	Some completely unrelated disclosures on the url link